DEF 14A: Foghorn Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Foghorn Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to elect directors and ratify the selection of its independent accounting firm.

Summary

• Foghorn Therapeutics Inc. will hold its 2024 Annual Meeting of Stockholders on June 26, 2024, at 9 a.m. Eastern Time, as a virtual-only meeting.
• Stockholders must register at www.proxydocs.com/FHTX to attend the meeting.
• The meeting will address the election of Scott Biller, Thomas J. Lynch, and Michael Mendelsohn as Class I directors for three-year terms.
• The stockholders will also vote to ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting for the director nominees and for the ratification of Deloitte & Touche LLP.
• The record date for determining stockholders entitled to vote is April 29, 2024.
• As of April 29, 2024, there were 42,585,616 shares of common stock outstanding and entitled to vote.
• The proxy statement and the Annual Report on Form 10-K for the year ended December 31, 2023, are available at www.proxydocs.com/FHTX.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting necessary information for the annual meeting. The tone is professional and neutral, with no significant positive or negative indicators.

Positives

• The Board of Directors is actively engaged in corporate governance, as evidenced by the detailed proxy statement.
• Stockholders have multiple avenues to vote, including online, telephone, mail, and virtually during the Annual Meeting.
• The company provides clear information on how to access proxy materials and the Annual Report.
• The company has a clawback policy in place to recover compensation from executive officers in the event of a financial restatement due to material noncompliance with financial reporting requirements.

Risks

• The division of the Board of Directors into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• The company is an emerging growth company and relies on exemptions from certain disclosure requirements, which could limit the information available to investors.
• The company's insider trading policy prohibits certain transactions in its securities, which could limit the ability of directors, officers, and employees to manage their investment risk.

Future Outlook

The document outlines the agenda and procedures for the upcoming Annual Meeting of Stockholders, focusing on the election of directors and ratification of the independent accounting firm. No specific forward-looking financial guidance is provided.

Management Comments

• Adrian Gottschalk, Chief Executive Officer, extends a cordial invitation to all stockholders to attend the virtual-only Annual Meeting.
• The Board of Directors recommends that you vote for each nominee for Class I director (Proposal No. 1) and for ratification of the proposed independent registered public accounting firm (Proposal No. 2).

Industry Context

This announcement is a standard part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions regarding the company's leadership and financial oversight. The virtual-only format reflects a growing trend in annual meetings, driven by cost savings and increased accessibility.

Comparison to Industry Standards

• The director compensation policy is in line with industry standards for biotech companies of similar size and stage.
• The use of a virtual-only format for the annual meeting is becoming increasingly common among public companies.
• The company's corporate governance practices, such as the adoption of a clawback policy and a related person transaction policy, are consistent with best practices for public companies.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a consulting agreement with Cigall Kadoch, Ph.D., a holder of 8.57% of the company's common stock, for advisory services related to chromatin remodeling.
• The company has a strategic collaboration with Loxo Oncology at Eli Lilly and Company, which owns 4,000,000 shares of the company's common stock.

Stakeholder Impact

• Shareholders are provided with the opportunity to vote on key decisions regarding the company's leadership and financial oversight.
• Executive officers are subject to a clawback policy, which could impact their compensation in the event of a financial restatement.
• Directors are provided with indemnification agreements and directors and officers liability insurance, which protects them from certain liabilities.

Next Steps

• Stockholders are encouraged to vote their shares by following the instructions provided in the Important Notice Regarding the Availability of Proxy Materials.
• Stockholders who wish to attend the virtual-only Annual Meeting must register at www.proxydocs.com/FHTX.
• The Board of Directors will consider the results of the votes on the proposals at the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Deloitte & Touche LLP, Stockholders, Corporate Governance, Executive Compensation, Foghorn Therapeutics